Patient-Reported Outcomes Data From TiNivo-2: Tivozanib and Nivolumab for RCC

Katy Beckermann, MD, PhD, medical director of genitourinary cancer research at Tennessee Oncology, discusses patient-reported outcomes (PROs) on quality of life from the phase 3 TiNivo-2 study. The findings reflect PROs comparing tivozanib combined with nivolumab versus tivozanib alone in renal cell carcinoma patients who had previously undergone immune checkpoint inhibitor therapy. Dr. Beckermann sheds light on the implications of these results for treatment strategies and patient quality of life.